BioSpace News Archive

Drug Development

Lilly’s Retatrutide Weight Loss Drug Scores in Mid-Stage Study

Patients treated in a Phase II study with Lilly’s retatrutide saw up to 24% weight loss at 48 weeks, driven by a triagonist mode of action that can bind and activate the GLP-1, GIP and glucagon receptors.

June 27, 2023
·
2 min read
·
Tristan Manalac
Policy

How Do Biopharma Investors Navigate Advisory Board Conflicts of Interest?

Recent changes in the board of directors at Biogen has garnered attention due to potential conflicts of interest. Such conflicts vary widely, but one thing is clear: perception matters.

June 27, 2023
·
4 min read
·
Claire Jarvis
Drug Development

Sanofi’s $1.4B Bet Pays Off with Promising Phase II Eczema Data

Though the topline data were sparse, Sanofi’s potentially first-in-class candidate amlitelimab improved Eczema Area and Severity Index scores in patients with moderate-to-severe atopic dermatitis.

June 27, 2023
·
2 min read
·
Tristan Manalac
Drug Development

MoonLake Looks to Raise $250M in Stock Offering on Heels of Mid-Stage Data

Phase II results of MoonLake’s sonelokimab suggest superiority to the competition. Funds raised in the stock offering will support Phase III trials with an anticipated launch in 2027.

June 27, 2023
·
2 min read
·
Kate Goodwin
Career Advice

10 Biotechnology Careers that Don’t Involve Bench Work

Here are 10 career paths to consider that don’t include bench work, along with role descriptions and links to jobs available now on BioSpace’s job board.

June 27, 2023
·
3 min read
·
Rosemary Scott
Policy

Ipsen Wins FDA’s Adcomm Support for Rare Disease Drug

An FDA advisory committee voted Wednesday that Ipsen’s fibrodysplasia ossificans progressive candidate palovarotene was effective and the benefits of the drug outweighed its risks.

June 27, 2023
·
3 min read
·
Tristan Manalac & Lisa Munger
Drug Development

FDA Approves UCB’s Twin-Use Drug for Rare Muscle-Wasting Disease

The biopharma’s monoclonal antibody is the first to win approval for the two most common forms of generalized myasthenia gravis, a rare autoimmune and neuromuscular disorder.

June 27, 2023
·
2 min read
·
David Adam
Drug Development

Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

The primary endpoint was met in a Phase 2b study of amlitelimab in adults with moderate-to-severe atopic dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.

June 27, 2023
·
6 min read
Biotech Beach

European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

ONK Therapeutics Ltd announced that the European Patent Office has granted its licensed patent covering CISH knockout in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells.

June 27, 2023
·
4 min read
Biotech Beach

Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMD

Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced positive data from a non-human primate study.

June 27, 2023
·
4 min read